251 related articles for article (PubMed ID: 23184698)
1. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.
Axlund SD; Yoo BH; Rosen RB; Schaack J; Kabos P; Labarbera DV; Sartorius CA
Horm Cancer; 2013 Feb; 4(1):36-49. PubMed ID: 23184698
[TBL] [Abstract][Full Text] [Related]
2. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.
Yoo BH; Axlund SD; Kabos P; Reid BG; Schaack J; Sartorius CA; LaBarbera DV
J Biomol Screen; 2012 Oct; 17(9):1211-20. PubMed ID: 22751729
[TBL] [Abstract][Full Text] [Related]
3. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
[TBL] [Abstract][Full Text] [Related]
4. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells.
Fettig LM; McGinn O; Finlay-Schultz J; LaBarbera DV; Nordeen SK; Sartorius CA
Oncogene; 2017 Nov; 36(44):6074-6084. PubMed ID: 28692043
[TBL] [Abstract][Full Text] [Related]
5. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.
Finlay-Schultz J; Cittelly DM; Hendricks P; Patel P; Kabos P; Jacobsen BM; Richer JK; Sartorius CA
Oncogene; 2015 Jul; 34(28):3676-87. PubMed ID: 25241899
[TBL] [Abstract][Full Text] [Related]
6. Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.
Knox AJ; Scaling AL; Pinto MP; Bliesner BS; Haughian JM; Abdel-Hafiz HA; Horwitz KB
Breast Cancer Res; 2014 Aug; 16(4):418. PubMed ID: 25116921
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.
Kabos P; Haughian JM; Wang X; Dye WW; Finlayson C; Elias A; Horwitz KB; Sartorius CA
Breast Cancer Res Treat; 2011 Jul; 128(1):45-55. PubMed ID: 20665103
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 5 alters β-catenin dynamics in breast cancer cells.
McGinn O; Ward AV; Fettig LM; Riley D; Ivie J; Paul KV; Kabos P; Finlay-Schultz J; Sartorius CA
Oncogene; 2020 Mar; 39(12):2478-2492. PubMed ID: 31988452
[TBL] [Abstract][Full Text] [Related]
9. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
[TBL] [Abstract][Full Text] [Related]
10. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
Horwitz KB; Dye WW; Harrell JC; Kabos P; Sartorius CA
Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5774-9. PubMed ID: 18391223
[TBL] [Abstract][Full Text] [Related]
11. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract][Full Text] [Related]
12. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.
Knutson TP; Truong TH; Ma S; Brady NJ; Sullivan ME; Raj G; Schwertfeger KL; Lange CA
J Hematol Oncol; 2017 Apr; 10(1):89. PubMed ID: 28412963
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha.
Perkins MS; Louw-du Toit R; Jackson H; Simons M; Africander D
Front Endocrinol (Lausanne); 2022; 13():959396. PubMed ID: 36187129
[TBL] [Abstract][Full Text] [Related]
14. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation.
Liu R; Zhou Z; Zhao D; Chen C
Mol Endocrinol; 2011 Jul; 25(7):1137-44. PubMed ID: 21566082
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Marotti JD; Collins LC; Hu R; Tamimi RM
Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
[TBL] [Abstract][Full Text] [Related]
16. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.
Cittelly DM; Finlay-Schultz J; Howe EN; Spoelstra NS; Axlund SD; Hendricks P; Jacobsen BM; Sartorius CA; Richer JK
Oncogene; 2013 May; 32(20):2555-64. PubMed ID: 22751119
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.
Haughian JM; Pinto MP; Harrell JC; Bliesner BS; Joensuu KM; Dye WW; Sartorius CA; Tan AC; Heikkilä P; Perou CM; Horwitz KB
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2742-7. PubMed ID: 21969591
[TBL] [Abstract][Full Text] [Related]
18. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
[TBL] [Abstract][Full Text] [Related]
19. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
20. Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.
Mohammadizadeh F; Naimi A; Rajabi P; Ghasemibasir H; Eftekhari A
Indian J Med Sci; 2009 Apr; 63(4):152-62. PubMed ID: 19414985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
